{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:11:55Z","timestamp":1780607515005,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jbspin.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T17:15:57Z","timestamp":1449940557000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study"],"prefix":"10.1016","volume":"83","author":[{"given":"Ilias","family":"Lazarou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Gascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg D.","family":"Seebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Andr\u00e9","family":"Guerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2015.05.012_bib0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0170","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0195","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0200","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0205","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0210","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar3397","article-title":"Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label","volume":"13","author":"Diaz-Lagares","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0220","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10067-013-2351-y","article-title":"Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis\u00a0\u2013\u00a0a case series","volume":"33","author":"Knight","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0225","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0240","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab Registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0245","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab Registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0250","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03009742.2011.620573","article-title":"Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients","volume":"41","author":"Wendt","year":"2012","journal-title":"Scandinavian J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0260","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar3901","article-title":"B lymphocyte-typing for prediction of clinical response to rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0265","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/ard.2009.125526","article-title":"EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0270","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","article-title":"Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0","volume":"34","author":"Cobo-Ibanez","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0275","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0280","first-page":"468","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0290","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab","volume":"41","author":"Abdulkader","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0295","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0300","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0305","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3899\/jrheum.110610","article-title":"Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register","volume":"39","author":"Soliman","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2249.2011.04390.x","article-title":"Key aspects for successful immunoglobulin therapy of primary immunodeficiencies","volume":"164","author":"Cunningham-Rundles","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0315","first-page":"1","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"0","author":"Vital","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.05.012_bib0320","article-title":"Primary endpoint failure in the rituximab in ANCA-associated vasculitis trial","volume":"64","author":"Miloslavsky","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T02:52:48Z","timestamp":1537152768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X15002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1297319X15002493"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.05.012","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}